Hives, or what doctors call urticaria, are red, itchy, and sometimes painful welts that show up on your skin. If you have chronic spontaneous urticaria (CSU), your hives occur spontaneously and recur ...

The first head-to-head randomized clinical trial to compare biologics in severe chronic rhinosinusitis with nasal polyps ...

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to ...

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in the ...

An announcement from Sanofi ( ($SNY) ) is now available. On September 22, 2025, Sanofi and Regeneron announced that their drug Dupixent received a ...

With $17 billion in annual sales, Dupixent is a franchise drug for its 50/50 owners Sanofi and Regeneron Pharmaceuticals. So rivals have lined up to challenge the antibody treatment against autoimmune ...